Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Zilong Hu
Improving Immunotherapy for Colorectal Cancer Using Dendritic Cells Combined With Anti-Programmed Death-Ligand In�vitro
Oncology Letters
Cancer Research
Oncology
Related publications
Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy
JAMA Dermatology
Dermatology
Medicine
Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Clinical Cancer Research
Cancer Research
Oncology
In�vitro Generation of Cytotoxic T�lymphocyte Response Using Dendritic Cell Immunotherapy in Osteosarcoma
Oncology Letters
Cancer Research
Oncology
Clinicopathological Significance and Prognostic Implication of Programmed Death-1 Ligand 2 Expression in Colorectal Cancer
International Journal of Biological Markers
Oncology
Cancer Research
Clinical Biochemistry
Forensic Medicine
Medicine
Pathology
Cancer Immunotherapy With Immunomodulatory Anti-Cd137 and Anti-Pd-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Cancer Discovery
Oncology
Antitumor Effects of the Silencing of Programmed Cell Death Ligand�1 in Colorectal Cancer via Immunoregulation
Oncology Reports
Medicine
Cancer Research
Oncology
Topotecan Decreases the Expression of Programmed Death-Ligand 1 in Glioblastoma Cell Lines; Implications for Immunotherapy
Matters
Anti-Programmed Cell Death Protein-1/Ligand-1 Therapy in Different Cancers
British Journal of Cancer
Cancer Research
Oncology
